Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.
نویسنده
چکیده
Ixabepilone (Ixempra) is a member of a new class of cytotoxic agents, the epothilones. Epothilones promote tubulin polymerization in vitro and demonstrate antitumor activity. This article reviews the preclinical and clinical data that have led to the approval of ixabepilone for patients with locally advanced or metastatic breast cancer for whom anthracycline and taxane treatments have failed.
منابع مشابه
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
Ixabepilone (Ixempra(®); Bristol-Myers Squibb) is a novel microtubule stabilizing agent recently approved for the treatment of metastatic breast cancer (MBC). This article focuses on considerations for ixabepilone administration and adverse event (AE) management, drawing from the biomedical literature indexed in PubMed, published abstracts from the American Society of Clinical Oncology annual m...
متن کاملManagement of advanced breast cancer with the epothilone B analog, ixabepilone
Despite the activity of standard chemotherapies in advanced breast cancer, disease progression remains inevitable. Most patients exposed to anthracyclines and taxanes develop resistance and a significant subset shows primary resistance. The increasing use of these agents as adjuvant therapy may result in more anthracycline- and taxane-resistant patients in the metastatic setting; few treatment ...
متن کاملDDDT-3122-management of advanced breast cancer
Correspondence: william J Gradishar robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 North St. Clair, Suite 850, Chicago, iL, 60611, USA Tel +1 312-695-4541 Fax +1 312-695-6189 email [email protected] Abstract: Despite the activity of standard chemotherapies in advanced breast cancer, disease progression remains inevitable. Most pat...
متن کاملIxabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
PURPOSE The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage, and administration of ixabepilone in patients with metastatic breast cancer are examined. SUMMARY The clinical utility of the three main classes of chemotherapeutic agents used in breast cancer (i.e., anthracyclines, taxanes, and fluorinated pyrimidines) is limited in some patients by the emergence of drug resistan...
متن کاملIxabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
Breast Cancer is the most prevalent cancer in the world with 4.4 million survivors up to 5 years following the diagnosis.1 In the US alone approximately forty thousand women die annually of metastatic breast cancer (MBC). Despite many effective systemic treatment options approximately 50% of women with MBC succumb to the disease within 24 months of the diagnosis.2 Ixabepilone is a novel, first ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 33 9 شماره
صفحات -
تاریخ انتشار 2008